Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

52
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
52
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A transferrin receptor-based vector enables robust Type-II membrane protein display on mammalian cells.

Biochemical and biophysical research communications·2026
Same author

<i>Plasmodium falciparum</i> leucine-rich repeat 5 disruption alters the transcription progression during asexual and sexual stage development.

mSphere·2026
Same author

Fouling-Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing.

Biotechnology and bioengineering·2026
Same author

The spatial proteome of the Plasmodium falciparum schizont illuminates the composition and evolutionary trajectories of its organelles.

Nature communications·2026
Same author

High-recovery AAV clarification using a multiplexed spiral inertial microfluidic platform.

Lab on a chip·2026
Same author

Identification of a Rejection Signature and Distinct Inflammatory Alveolar Macrophage Populations Post-lung Transplantation.

Transplantation·2026

Related Experiment Video

Updated: Apr 6, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

626

Basigin is a druggable target for host-oriented antimalarial interventions.

Zenon A Zenonos1, Sara K Dummler2, Nicole Müller-Sienerth3

  • 1Cell Surface Signalling Laboratory and Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK Cell Surface Signalling Laboratory and Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK.

The Journal of Experimental Medicine
|July 22, 2015
PubMed
Summary

A new antibody therapy targeting the host protein basigin effectively blocks Plasmodium falciparum invasion and clears malaria infections. This host-targeted approach offers a promising strategy against drug-resistant malaria parasites.

More Related Videos

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

23.9K

Related Experiment Videos

Last Updated: Apr 6, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

626
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

23.9K

Area of Science:

  • Malariology
  • Immunology
  • Drug Discovery

Background:

  • Plasmodium falciparum causes severe malaria, a major global health issue, particularly in children.
  • Drug-resistant malaria parasites limit the effectiveness of current antimalarial drugs.
  • Targeting host factors essential for parasite survival presents an alternative therapeutic strategy.

Purpose of the Study:

  • To develop and evaluate a novel host-targeted therapeutic for malaria.
  • To investigate the potential of targeting the erythrocyte receptor basigin for malaria treatment.

Main Methods:

  • Development of a recombinant chimeric antibody (Ab-1) targeting basigin.
  • In vitro assessment of Ab-1's ability to inhibit the PfRH5-basigin interaction and erythrocyte invasion.
  • In vivo evaluation of Ab-1's efficacy in clearing established P. falciparum infections in a mouse model.

Main Results:

  • Ab-1 effectively inhibited the interaction between P. falciparum RH5 (PfRH5) and its host receptor, basigin.
  • The antibody potently blocked erythrocyte invasion by all tested P. falciparum strains.
  • Ab-1 rapidly cleared existing P. falciparum blood-stage infections in vivo with no observed toxicity.

Conclusions:

  • Antibodies targeting host basigin represent a viable therapeutic strategy against malaria.
  • This host-directed approach shows potential for treating infections caused by multi-drug resistant Plasmodium falciparum.
  • Targeting host factors offers a new avenue for combating malaria and overcoming drug resistance.